FY2025 EPS Estimates for ACAD Decreased by Cantor Fitzgerald

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of ACADIA Pharmaceuticals in a research report issued on Thursday, February 27th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will earn $0.15 per share for the year, down from their prior estimate of $0.24. Cantor Fitzgerald has a “Overweight” rating and a $28.00 price target on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share.

A number of other analysts have also recently weighed in on ACAD. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday. Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday. StockNews.com cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Guggenheim cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $23.00 to $20.00 in a research report on Friday, January 3rd. Nine investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.00.

ACADIA Pharmaceuticals Trading Up 1.3 %

Shares of ACADIA Pharmaceuticals stock opened at $19.60 on Friday. The company has a fifty day moving average price of $18.37 and a 200 day moving average price of $16.81. ACADIA Pharmaceuticals has a twelve month low of $14.15 and a twelve month high of $24.53. The stock has a market cap of $3.26 billion, a price-to-earnings ratio of 25.13 and a beta of 0.37.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Jefferies Financial Group Inc. acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter worth about $2,106,000. Mackenzie Financial Corp raised its stake in ACADIA Pharmaceuticals by 180.1% during the fourth quarter. Mackenzie Financial Corp now owns 51,065 shares of the biopharmaceutical company’s stock worth $937,000 after acquiring an additional 32,833 shares during the period. GF Fund Management CO. LTD. acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter worth about $64,000. CTC Alternative Strategies Ltd. acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter worth about $1,012,000. Finally, Neo Ivy Capital Management raised its stake in ACADIA Pharmaceuticals by 1,551.5% during the fourth quarter. Neo Ivy Capital Management now owns 57,504 shares of the biopharmaceutical company’s stock worth $1,055,000 after acquiring an additional 54,022 shares during the period. Institutional investors and hedge funds own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.